Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma.

Blood cancer journal·2026
Same author

CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma.

HemaSphere·2026
Same author

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicine·2026
Same author

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.

Blood advances·2026
Same author

Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.

Case reports in hematology·2026
Same author

Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS.

Blood advances·2026
Same journal

Spatially defined microenvironmental niches are associated with clinical outcome and tumor ecosystem diversity in head and neck cancer.

Med (New York, N.Y.)·2026
Same journal

AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.

Med (New York, N.Y.)·2026
Same journal

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026
Same journal

Atlas of human brain imaging-derived phenotypes and disease risk.

Med (New York, N.Y.)·2026
Same journal

Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine.

Med (New York, N.Y.)·2026
Same journal

Rethinking parenteral nutrition as supportive therapy for neonatal sepsis.

Med (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Five trials reshaping multiple myeloma.

Alexis Talbot1, Arthur Bobin2, Cyrille Touzeau3

  • 1Immuno-Hematology Department, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, UMR 1342, Université Paris Cité, Paris, France.

Med (New York, N.Y.)
|June 12, 2026
PubMed
Summary
This summary is machine-generated.

New multiple myeloma therapies may offer durable remission, moving beyond continuous control. Research explores strategies like MRD-guided treatment and immune redirection for potential cures.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Jun 14, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Current multiple myeloma treatment focuses on continuous disease control.
  • Achieving long-term, durable remission remains a significant challenge in multiple myeloma management.

Purpose of the Study:

  • To review emerging therapies in multiple myeloma that challenge existing treatment paradigms.
  • To explore novel strategies that may lead to treatment-free remission and potential cures for multiple myeloma.

Main Methods:

  • Analysis of five pivotal clinical trials evaluating transformative strategies in multiple myeloma.
  • Focus on strategies including replacement of transplantation, minimal residual disease (MRD)-guided treatment, finite therapy, multi-target immune redirection, and early interception.

Main Results:

  • Emerging therapies are demonstrating the potential to achieve durable remission in multiple myeloma.
  • These novel approaches challenge the traditional paradigm of continuous disease control.

Conclusions:

  • Pivotal trials suggest a shift towards biology-driven, immune-based treatment frameworks for multiple myeloma.
  • These advancements hold promise for achieving treatment-free remission and ultimately curing multiple myeloma.